Related Experiment Video
Updated: Nov 3, 2025
Murine Prostate Micro-dissection and Surgical Castration
Published on: May 11, 2016
LIMK2-NKX3.1 Engagement Promotes Castration-Resistant Prostate Cancer
Moloud A Sooreshjani1, Kumar Nikhil1, Mohini Kamra1
1Department of Chemistry and Purdue University Center for Cancer Research, Purdue University, 560 Oval Drive, West Lafayette, IN 47907, USA.
Abstract:
NKX3.1's downregulation is strongly associated with prostate cancer (PCa) initiation, progression, and CRPC development. Nevertheless, a clear disagreement exists between NKX3.1 protein and mRNA levels in PCa tissues, indicating that its regulation at a post-translational level plays a vital role. This study identified a strong negative relationship between NKX3.1 and LIMK2, which is critical in CRPC pathogenesis. We identified that NKX3.1 degradation by direct phosphorylation by LIMK2 is crucial for promoting oncogenicity in CRPC cells and in vivo. LIMK2 also downregulates NKX3.1 mRNA levels. In return, NKX3.1 promotes LIMK2's ubiquitylation. Thus, the negative crosstalk between LIMK2-NKX3.1 regulates AR, ARv7, and AKT signaling, promoting aggressive phenotypes. We also provide a new link between NKX3.1 and PTEN, both of which are downregulated by LIMK2. PTEN loss is strongly linked with NKX3.1 downregulation. As NKX3.1 is a prostate-specific tumor suppressor, preserving its levels by LIMK2 inhibition provides a tremendous opportunity for developing targeted therapy in CRPC. Further, as NKX3.1 downregulates AR transcription and inhibits AKT signaling, restoring its levels by inhibiting LIMK2 is expected to be especially beneficial by co-targeting two driver pathways in tandem, a highly desirable requisite for developing effective PCa therapeutics.
Insights
NKX3.1, a prostate cancer tumor suppressor, is degraded by LIMK2. Inhibiting LIMK2 restores NKX3.1 levels, offering a new therapeutic strategy for aggressive prostate cancer (PCa).
Area of Science:
- Oncology
- Molecular Biology
- Urology
Background:
- Downregulation of NKX3.1 is linked to prostate cancer (PCa) initiation, progression, and castration-resistant prostate cancer (CRPC).
- Discrepancies between NKX3.1 protein and mRNA levels suggest post-translational regulation is critical in PCa.
- LIMK2 is implicated in CRPC pathogenesis.
Purpose of the Study:
- To investigate the regulatory relationship between NKX3.1 and LIMK2 in prostate cancer.
- To elucidate the role of this interaction in CRPC development and aggressive phenotypes.
- To explore the therapeutic potential of targeting this pathway.
Main Methods:
- Investigated the interaction between NKX3.1 and LIMK2 in CRPC cells and in vivo models.
- Assessed the impact of LIMK2 on NKX3.1 protein and mRNA levels.
- Examined the effects of the LIMK2-NKX3.1 axis on AR, ARv7, AKT signaling, and PTEN.
- Evaluated the therapeutic implications of LIMK2 inhibition.
Main Results:
- Identified a direct negative relationship where LIMK2 phosphorylates and degrades NKX3.1, promoting oncogenicity.
- LIMK2 was found to downregulate NKX3.1 mRNA levels and promote NKX3.1 ubiquitylation.
- Negative crosstalk between LIMK2 and NKX3.1 regulates AR, ARv7, and AKT signaling, driving aggressive phenotypes.
- LIMK2 also downregulates PTEN, which is linked to NKX3.1 loss.
Conclusions:
- The LIMK2-NKX3.1 axis is a critical regulator of aggressive prostate cancer phenotypes.
- Targeting LIMK2 to preserve NKX3.1 levels presents a promising therapeutic strategy for CRPC.
- Inhibiting LIMK2 may co-target AR and AKT signaling pathways, crucial for effective PCa treatment.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019